About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, June 17th, 2013

The QualityStocks
Daily Stock List


Discovery Laboratories, Inc. (DSCO)

StreetInsider, WiseAlerts, MonsterStocksPicks, Stock Stars, The Motley Fool, and FeedBlitz reported earlier on Discovery Laboratories, Inc. (DSCO), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Based in Warrington, Pennsylvania, Discovery Laboratories, Inc. is a specialty biotechnology company whose dedication is to advancing a new standard in respiratory critical care via the development of novel technologies. The Company is focusing on two primary areas of development. One is their proprietary KL4 surfactant technology. The second is their novel drug delivery technologies to deliver aerosolized respiratory medicines, including their KL4 surfactant.

Discovery Laboratories' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant. It is structurally comparable to pulmonary surfactant. The Company's strategy is initially concentrating on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. AEROSURF (lucinactant for inhalation), their initial aerosolized KL4 surfactant product, is under development to address respiratory distress syndrome in premature infants.

Their products include SURFAXIN®. SURFAXIN (lucinactant) intratracheal suspension is a synthetic, peptide-containing surfactant. SURFAXIN is indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

Additionally, their products include AFECTAIR. The development of the AFECTAIR technology was as a proprietary, disposable device that simplifies the delivery of aerosolized medications to critical-care patients requiring ventilatory support including intermittent mechanical ventilation or continuous positive airway pressure. Moreover, Discovery Laboratories is pursuing European Conformity (CE) marking for potential commercialization of AFECTAIR for infants in the European Union (EU) this year.

Last week, Discovery Laboratories announced that on June 7, 2013 they submitted a response to the U.S. Food and Drug Administration's (FDA) recent correspondence relating to the Company's recently updated product specifications for SURFAXIN®.  Discovery Labs expects that the FDA may take up to four months to review the information provided. If their plan is successful and the FDA agrees with the response, Discovery Labs expects to go ahead with the commercial introduction of SURFAXIN in the fourth quarter of this year.

In addition, last week, the Company announced the presentation of the last in a series of pharmacoeconomic analyses. These indicate that a reduction in the rate of reintubation among preterm infants may potentially result in hospital cost-savings related to fewer reintubation-related diagnoses of bronchopulmonary dysplasia (BPD), air leak, sepsis, necrotizing enterocolitis (NEC), or intraventricular hemorrhage (IVH). This includes savings of up to $562,000 per 100 patients diagnosed with BPD. The findings from this third and final pharmacoeconomic analysis were presented recently at the 2013 Pediatric Pharmacy Advocacy Group (PPAG) Annual Meeting held in Indianapolis, Indiana.

Discovery Laboratories, Inc. (DSCO), closed Monday's trading session at $1.66, up 1.84%, on 192,612 volume with 835 trades. The average volume for the last 60 days is 451,440 and the stock's 52-week low/high is $1.50/$3.51.

Red Giant Entertainment, Inc. (REDG)

PennyStockLocks.com, PennyStocks24, Penny Stock Newsletter, PREPUMP STOCKS, Damn Good Penny Picks, Stock Roach, and StockHideout reported earlier on Red Giant Entertainment, Inc. (REDG), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Red Giant Entertainment, Inc. is an intellectual property (IP) development company. The intention of their properties (comic book style) is to undergo development for the comic book market and for use in other media (movies, video games, and television, novels, toys, apparel and telephone wireless applications). Each week a new comic book targeting a different audience demographic will undergo distribution at one million copies across the network. The Company has more than 36 titles in their library.
Their business plan is to either engage in the direct production of their properties or enter into licensing agreements with others. Red Giant has a number of movies in different stages of production, and more are currently undergoing development. Red Giant Entertainment's primary business is committed to developing quality intellectual properties, while serving their advertisers.

The Company is currently the largest publisher of exclusive comic book format material on the internet. Their print division is positioned to become the largest internationally, with an annual circulation of over 52 million.

The intention of the products is for them to be available for others to purchase advertising on terms and conditions to be determined by the licensee of the product. Red Giant intends to retain a royalty for the product and for the included advertising content. Merchandise revenue related to the product will also be available to Red Giant on terms and conditions to be negotiated between the licensee and the Company or retained by the Company.

Earlier this month, Red Giant Entertainment announced that during their quarter that ended May 2013, their ad impressions were greater than 95 million served. This is more than a 100 percent increase from any prior quarter. The acquisition of ComicGenesis.com, as well as new comics helped the Company break records.

Last week, the Company announced the launch of Porcelain, a new weekly action comic book series online. There will be a serialized comic at the Company's host and strategic partner, Keenspot.com, which is promoting Porcelain across their entire network. It will also be available as a print comic, making its debut at the Comic Convention in San Diego, California.

Red Giant Entertainment, Inc. (REDG), closed Monday's trading session at $0.012, up 2.56%, on 403,195 volume with 29 trades. The average volume for the last 60 days is 6,164,456 and the stock's 52-week low/high is $0.0081/$0.26.

Titan Energy Worldwide, Inc. (TEWI)

The Stock Psycho, Darth Trader, Top Gun, Topgun stockpicks, PennyStocks24, and Real Pennies reported earlier on Titan Energy Worldwide, Inc. (TEWI), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in Eden Prairie, Minnesota, Titan Energy Worldwide, Inc.'s dedication is to assisting companies in meeting their power generation and energy management needs. To date the Company has focused on providing thousands of customers with the most advanced power generation equipment to enable their operations to continue uninterrupted during times of power failures or disasters. Concerning energy management, Titan offers emergency and backup power technologies, demand response programs and Smart Grid applications, and more. Titan Energy Worldwide's shares trade on the OTC Markets' OTCQB.  

The Company is a leader in distributed power generation products and intelligent energy management services. They serve the disaster recovery; first responder; relief agency; homeland security; Department of Defense, and municipality sectors. Titan combines engineering expertise, established sales and distributorships, service operations, and unique strategic partnerships to meet the growing demand in the U.S and internationally for clean, efficient, energy solutions. The Company serves as a distributor for power generation equipment, a national service provider for onsite power systems, and a manufacturer of advanced monitoring and asset management technologies. 

Titan Energy Worldwide, in 2006, acquired Stellar Energy, a Minneapolis-based provider of power generation equipment and service. Stellar Energy is now Titan Energy Systems (TES). They've expanded their number of sales and service offices to include Nebraska, Iowa, North and South Dakota, New York, New Jersey and Connecticut. TES provides Titan Energy Worldwide and their satellite offices with accounting and administrative support. 
In 2009, the Company acquired the Industrial and Service Division of RB Grove, a power generation provider located in Miami, Florida. This company now goes by the name Grove Power, Inc. Grove Power is responsible for Titan's long term goal of expansion throughout the Southeastern U.S. 
Titan Energy Worldwide acquired a power generation business in New Jersey in 2009.  They provide the Company with purchase orders, backlog and extensive customer and marketing relationships in New York, Connecticut and New Jersey. This business has merged into TES. 
In 2010, Titan Energy Development, Inc. (TEDI) purchased certain assets and assumed certain liabilities of Stanza Systems, which provides the Company with a software development company experienced in smart grid and utility operations. They operate this business as Stanza Technologies. Stanza has developed network communications software that Titan plans to utilize in their generator service business.  

Earlier this month, Titan Energy Worldwide announced that they posted record sales of over $2.6 million for the month of April 2013.  These record revenues were due to $1.7 million in equipment sales for the month. The Company also expects to exceed the $2 million mark in monthly sales for May and June 2013. 

Titan Energy Worldwide, Inc. (TEWI), closed Monday's trading session at $0.039, up 50.00%, on 10,255,129 volume with 649 trades. The average volume for the last 60 days is 342,190 and the stock's 52-week low/high is $0.0048/$0.0684.

Asia Carbon Industries, Inc. (ACRB)

We are reporting on Asia Carbon Industries, Inc. (ACRB), here at the QualityStocks Daily Newsletter.

Trading on the OTCQB, Asia Carbon Industries, Inc. is a producer of a series of premium carbon black products under the brand name "Great Double Star." The Company, by way of their variable interest entity, Taiyuan Hongxing Carbon Black, Ltd., manufactures and sells carbon black products in China. Asia Carbon established in 2003 in Shanxi, the nation's highest coal producing province. The Company is one of the top ten carbon black producers in Shanxi province, China.
Asia Carbon Industries is based in New York City.

Carbon black is a deep, black powder with many applications. It derives from the controlled combustion of coal tar or residual oil feedstock. Carbon black's desirable chemical properties make it a vital raw material for a number of industries. Asia Carbon Industries has established relationships with a high-profile customer base. The Company is expanding their manufacturing capacity to meet the growing demand for their products.

Carbon black is extensively used within the rubber industry as reinforcing filler. It is used in the paint and coating industry as a coloring agent. Moreover, carbon black is used in batteries as a conductive agent. The great majority of carbon black is used by the tire industry, where it can improve rubber's strength, wear resistance, and life span. Therefore, this lowers the overall cost of tire products.

Asia Carbon Industries currently manufactures three carbon black products - one hard and two soft. Each has a relatively high profit margin. The price of hard carbon black is slightly higher than that of soft carbon black. The demand for hard carbon black is substantially higher than the demand for the soft. In addition, Asia Carbon sells Naphthalene Oil, a byproduct of the Company's manufacturing process.

In mid-May, Asia Carbon Industries announced their earnings for the quarter ended March 31, 2013. All operating results for the quarter were negatively impacted by the suspension of the Company's three dry production facilities for conversion to specialty carbon black production.

Net sales for the quarter ended March 31, 2013 were $5,963,945. This is 53 percent lower from $12,581,692 for the same period in 2012. Net income for the quarter ended March 31, 2013 was $389,953. This represents a decrease of 78 percent from $1,807,081 for the same period in 2012. Tonnage sales of carbon black were 7,268 in the quarter ended March 31, 2013. This represents a 47 percent decline versus the first quarter of 2012.

Asia Carbon Industries, Inc. (ACRB), closed Monday's trading session at $0.095, up 5.56%, on 149,000 volume with 9 trades. The average volume for the last 60 days is 65,723 and the stock's 52-week low/high is $0.076/$0.35.

SurePure, Inc. (SURP)

We are highlighting SurePure, Inc. (SURP), here at the QualityStocks Daily Newsletter.

Headquartered in New York City, SurePure, Inc. is a global leader in liquid photopurification. This is the green alternative to pasteurization and chemicals. Using their patented 'Turbulator' technology, SurePure systems use UV-C light to purify microbiologically sensitive liquids. The design of the Company's technology is to deliver food-grade solutions. Additionally, their technology can be harnessed to improve processing liquids such as water, brines and sugar syrup solutions, and animal blood plasma. SurePure lists on the OTC Markets' OTCQB.

The Company's technology offers greater microbiological efficacy than conventional UV systems. The technology is effective for clear and turbid liquids. SurePure also provides opportunities for the development of unique and differentiated products with desired consumer benefits, guaranteed food safety, and sound commercial benefits.

Their liquid photo-purification technology purifies the aforementioned turbid liquids. These include milk, beer, fruit juice, wine, carbonated beverages and an assortment of industrial applications. Their patented technology uses a specific band of ultraviolet light to provide a green alternative to heat and chemicals in the purification of turbid liquids.

Recently, SurePure announced Karbon Strateji Danismanlik Dis Ticaret Limited STI as the Company's exclusive distributor in Turkey. This relationship has yielded early breakthroughs. Commercial trials are already planned for the replacement of pasteurization of sugar syrup for one of the globe's largest carbonated soft drink companies, the replacement of pasteurization for a major dairy, the replacement of pasteurization for a liquid egg application and the shelf-life enhancement of a well-known fruit juice range.

Last week, SurePure announced that their patented Turbulator technology has been demonstrated to be effective in containing alicyclobacillus in fruit juice and fruit concentrates. The alicyclobacillus bacteria is a genus of Gram positive, rod-shaped and sporeforming bacteria found to grow in acidic conditions with the spores able to survive usual pasteurization procedures. Particularly, the Company's treatment method was shown to achieve, reliably, in excess of a 5 log10 reduction (99.99 percent) per 0.5 kJ L-1 of UV-C dosage in juice, water and concentrates inoculated with A. acidoterrestris.

SurePure, Inc. (SURP), closed Monday's trading session at $1.08, up 3.85%, on 66,400 volume with 19 trades. The average volume for the last 60 days is 10,866 and the stock's 52-week low/high is $0.84/$1.52.

Amerilithium Corp. (AMEL)

Stock Twiter reported recently on Amerilithium Corp. (AMEL), PennyStocks24, AskSlapper, TradeThesePicks, Investor News Source, Stock Stars, Monster Stocks Picks, Stock Analyzer, Jet-Life Penny Stocks, Penny Dreamers, Penny Champions did earlier, and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Amerilithium Corp. is a mining company whose commitment is to progressively developing into one of the leading U.S. companies in the international lithium industry. Lithium is a lightweight metal used in a broad spectrum of consumer products globally. The Company has amassed a lithium portfolio consisting of approximately 719,779 acres. These include four Nevada-based projects nearby the only lithium producing plant in the U.S., a large project in Alberta, Canada, and a project in Western Australia. Listed on the OTC Markets' OTCQB, Amerilithium has their headquarters in Henderson, Nevada. 

The Company's current plan of operations for the next 12 months is finalizing their Nevada drill program after carefully reviewing the results from their Gravity and CSMAT Geophysical Surveys in Nevada, and receiving the appropriate permits. Their plan is to complete compliant reports post drilling. Furthermore, after reviewing the results of their previous exploration of their Australian assets, Amerilithium, with the help of their strategic partner, is planning to finalize an exploration program on the companies' Australian based assets. 

Amerilithium's intention is to implement their exploration program in Australia after securing required funds. In addition, the Company is prepared to start their extended Nevada based drill program as soon as financially viable.
Recently, Amerilithium announced that they received a new technical report on their Jackson Wash Lithium Brine Project in Esmeralda County, Nevada. According to this Report, the Jackson Wash Project has the potential to contain economic lithium resources. Therefore, Amerilithium confirms the location of their previously identified 4 drill hole locations as part of a permitted 10-hole drilling exploration plan for the Jackson Wash Project designed to identify the presence, quantity, and quality of any lithium-bearing groundwater present in the property's subsurface.

The Jackson Wash property consists of 65 unpatented placer claims totaling 2,450 acres (991 hectares). The claims cover the Jackson Wash Basin Gravity Low, previously identified by a regional United States Geological Survey gravity investigation. The geologic formations that compose the surrounding mountain ranges contain unusually high concentrations of lithium.

Amerilithium Corp. (AMEL), closed Monday's trading session at $0.0043, up 4.88%, on 529,232 volume with 15 trades. The average volume for the last 60 days is 580,684 and the stock's 52-week low/high is $0.0037/$0.053.

Copper North Mining Corp. (COL.V)

Today we are reporting on Copper North Mining Corp. (COL.V), here at the QualityStocks Daily Newsletter.

Listed on the TSX Venture Exchange, Copper North Mining Corp. is a Canadian mineral exploration and development company. The Company began trading on October 24, 2011 on the TSX Venture Exchange (TSX.V: COL). Their assets include the Carmacks Copper Project in the Yukon, and the high-grade, stratiform-copper Redstone Property, in the Northwest Territories.  Copper North Mining has their corporate headquarters in Vancouver, British Columbia. 

The Company owns the Carmacks project 100 percent. The project is 220 km northwest of Whitehorse, Yukon. Carmacks is a near term producer and it has permitting for construction. It will produce 32 million pounds of cathode copper annually. A positive feasibility study completed in May of 2007; the mine type is open pit. 

In addition, Copper North Mining wholly owns the Redstone deposit. This deposit is in the Northwest Territories of Canada. Redstone is a high-grade deposit; its claims and leases extend over approximately 160 km. The primary metals are copper and silver and the mine type is underground. 

This past March, the Company announced that they engaged the services of M3 Engineering and Technology Corporation (Tucson, Arizona) to complete the basic engineering study for the main power supply to the Carmacks Copper Project.  
In January 2013, Copper North signed a Letter of Intent (LOI) with Yukon Energy Corporation (YEC) concerning entering into a Power Purchase Agreement (PPA) for the supply of electricity. The PPA will provide for YEC to supply Copper North with the electricity requirements for the Project from YEC's grid-based electricity generation, via YEC's transmission grid and the transmission connection from the Project to the Grid. 

Recently, Copper North Mining announced the signing of a loan agreement with an insider of the Company to secure funds of C$300,000.  The Company will use the proceeds from the Loan for general working capital.

Copper North Mining Corp. (COL.V), closed Monday's trading session at $0.06, up 9.09%, on 9,130 volume. The stock's 52-week low/high is $0.05/$0.20.

TOMI Environmental Solutions, Inc. (TOMZ)

Nebula Stocks reported previously on TOMI Environmental Solutions, Inc. (TOMZ), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Based in Beverly Hills, California, TOMI Environmental Solutions, Inc. is a global bacteria decontamination and infectious disease control company. The design of the Company's products is to service a wide assortment of commercial structures. Additionally, TOMI develops training programs and application protocols for their clients. TOMI is a member in good standing with the Indoor Air Quality Association, The International Ozone Association and The United States Green Building Council, The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and the Restoration Industry Association. TOMI Environmental Solutions lists on the OTCQB. 
TOMI provides green energy-efficient environmental solutions for indoor surface decontamination by way of sales and licensing of their premier platform of Hydrogen Peroxide aerosols, Ultra-Violet Ozone Generators and Ultra-Violet Germicidal Irradiation (UVGI) products and technologies. The Company's products service medical facilities, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, and athletic facilities. Additionally, their products and services have also been used in single-family homes and multi-unit residences. 
TOMI also intends to generate and support research on other air remediation solutions. These include hydroxyl radicals and other Reactive Oxygen Species (ROS). The Company also intends to form business alliances with major remediation companies, construction companies and corporations specializing in disaster relief.
In April, TOMI Environmental Solutions announced that they completed the acquisition of Binary Ionization Technology (BIT) and related patents from L-3 Applied Technologies, Inc. (L-3). This technology relates to a disinfection system that applies cold plasma activation to a hydrogen peroxide-based aerosol (BIT). L-3 will continue to have the exclusive license to sell BIT products covered by the transferred technology to the military. 

In late May, TOMI Environmental Solutions announced that they leased space in the San Diego, California metropolitan area for use as a research and development facility for their Binary Ionization Technology (BIT) equipment to enhance the functionality of the entire product line. Additionally, the facility will be used as a testing laboratory and quality control center for all products manufactured under TOMI's direction.  

TOMI Environmental Solutions, Inc. (TOMZ), closed Monday's trading session at $0.22, up 18.92%, on 78,611 volume with 14 trades. The average volume for the last 60 days is 41,325 and the stock's 52-week low/high is $0.015/$1.98.


The QualityStocks
Company Corner


The Aristocrat Group Corp. (ASCC)

The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $0.30, up 3.45%, on 136,136 volume with 54 trades. The stock’s average daily volume over the past 60 days is 322,171, and its 52-week low/high is $0.21/$1.25.

The Aristocrat Group Corp. wholesale subsidiary, TOP Shelf Distributing, reported they are in the process of obtaining wholesaler licensing today in one of the country's top markets, a key foothold that will grant their RWB Ultra-Premium Handcrafted Vodka immediate access to the $21.3 billion U.S. spirits industry. ASCC intends to take full advantage of the explosion in niche spirits and microbrews in recent years, moving beyond their own all-American spirit with federal approval to advertise its gluten-free status right on the label, with plans to market additional outside distilled spirits brands as well as importing select beers and wines.

The Aristocrat Group Corp. (ASCC) is a brand management company focused on providing premiere luxury goods through continual innovation. Luxuria Brands, a subsidiary of The Aristocrat Group, has been established to identify and promote unique brands that have mass market appeal across a diverse demographic.

Luxuria Brands is primarily concentrated on distilled spirits industries, with an initial focus on Vodka branding and marketing. The worldwide distilled spirits market is currently worth about $263 billion. In the U.S. alone, Vodka sales between 2004 and 2009 grew 25% from 13.9 million cases to 58.4 million cases. The clear liquor now accounts for almost a third of all distilled spirits consumed and continues to rise in popularity.

The Aristocrat Group is also pursuing opportunities in the women’s lifestyle industry. The World Bank recently estimated that the earning power of women will reach $18 trillion by 2014, which is twice the estimated 2014 GDP of China and India combined. The Aristocrat Group is working to bring fresh, innovative prenatal and postpartum solutions to women who are looking for a more comprehensive approach to wellness.

The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. The company aims to take a leadership position in multiple growing markets that offer opportunities for partnership, sponsorship, and brand awareness activities. The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. Disclaimer

The Aristocrat Group Corp. Company Blog

The Aristocrat Group Corp. News:

ASCC Begins Brand-Building Wholesale Initiative

ASCC Ready to Hit Market with Top Shelf Vodka Everyone Can Enjoy

ASCC Forms Vodka Distribution Strategy

DoMark Internatioxnal, Inc. (DOMK)

The QualityStocks Daily Newsletter would like to spotlight DoMark International, Inc. (DOMK). Today, DoMark International, Inc. closed trading at $0.12, up 0.84%, on 3,004,384 volume with 386 trades. The stock’s average daily volume over the past 60 days is 432,970, and its 52-week low/high is $0.0322/$1.32.

DoMark International, Inc. was pleased to report further strides in their infrared/solar charging systems leadership for Apple and Samsung devices today, as the announcement was made that another 158k orders have come in for the new IRCharger case for Apple iPhones, Samsung Galaxy Slll, and S4 smartphones ahead of the August 1st 2013 global launch date. CEO of DOMK, Andy Ritchie, couldn't hide his pride over the mounting interest from retailers expressed via the distribution partner network and tipped his hat to markets that they expect to announce many more orders in shortly.

DoMark International, Inc. (DOMK) is focused on researching, evaluating, and acquiring profitable private firms in the business segments of sports, technology, medical, energy, and business services. By providing the financial and human capital necessary to deal with overwhelming administrative, planning, governance, compliance, and regulatory challenges, its newly acquired partners can focus their energy and flourish.

Through its wholly owned subsidiary, SolaWerks, Inc., DoMark is committed to revolutionizing the efficiency and capabilities of a new generation of mobile devices. The subsidiary's current focus is on developing and distributing the SolaPad, a combined cover and charging system for Apple's iPad, and the SolaCase, a combined cover and charging system for all versions of Apple's iPhone.

Musclefoot, Inc., another wholly owned subsidiary of DoMark, is engaged in the distribution, marketing, and sale of Barefoot Science, the revolutionary patented foot care system designed to relieve foot and back pain as well as improve athletic performance. With a strong commitment to customer service and security, DoMark plans to expand its marketing relationships across a far broader product set.

The management team has positioned the company to capitalize on emerging opportunities by working with the world's most forward-thinking companies to develop and market game-changing products with the promise of long-term financial growth. Leveraging the expertise of its team, the company continues to evaluate acquisition candidates and products targeting underserved markets to increase its growth potential. Disclaimer

DoMark International, Inc. Blog

DoMark International, Inc. News:

DoMark International Inc. Engages Leading Global Designer to Develop a New Luxury Range of Accessory Products for the Apple iPad for the $200 Billion Luxury Product Market

DoMark International Inc. Develops New Product for $2.3 Billion iPad Accessories Market

DoMark International Inc. Positions Itself for Substantial Growth

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.04, even for the day, on 1,566,518 volume with 47 trades. The stock’s average daily volume over the past 60 days is 2,007,427, and its 52-week low/high is $0.0275/$0.155.

Advaxis Inc. reported on the results of their recent Annual Meeting of Stockholders, held in Princeton, NJ on June 14, which will be fully disclosed in an upcoming reported filing with the Securities and Exchange Commission. Among the results was enthusiastic support by the stockholders for the election of incumbents Thomas A. Moore, Roni A. Appel, Richard Berman, Dr. Thomas McKearn, and Dr. James Patton to the company's Board of Directors, as well as ratification of Marcum, LLP as the independent registered accountants for fiscal 2013.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Announces Results of 2013 Annual Meeting of Stockholders

Advaxis Requests Orphan Drug Designation for Treatment of HPV-Associated Head and Neck Cancer with ADXS-HPV

Advaxis Issues Letter Advising Stockholders to Vote FOR Proposals 2 and 3 of Proxy Statement

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.85, even for the day. The stock’s average daily volume over the past 60 days is 1,634, and its 52-week low/high is $0.06/$1.52.

VistaGen Therapeutics Inc. reported today on key developments involving its CardioSafe 3Dô and LiverSafe 3Dô bioassay systems presented in poster presentations at the 11th Annual Meeting of the International Society of Stem Cell Research (ISSCR), at the largest forum for stem cell and regenerative medicine professionals from around the world, June 12 to 15, 2013, in Boston, Massachusetts. It is a momentous time for stem cell research and VSTA is on the cutting-edge with their advanced bioassay systems.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics Presents CardioSafe 3Dô and LiverSafe 3Dô Developments at International Society of Stem Cell Research's 11th Annual Meeting

VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue

VistaGen Announces $36 Million Strategic Financing Agreement

The Aristocrat Group Corp. (ASCC) Launches Brand-Building Wholesale Initiative

The Aristocrat Group Corp. announced today that its wholesale subsidiary, TOP Shelf Distributing, is currently in the process of obtaining wholesaler licensing in one of the country’s top markets in the $21.3 billion U.S. spirits industry.

Expanding business via distribution deals with international distillers and brewers is an important part of the company’s overall business strategy. The first product slated for wholesale by TOP Shelf is RWB Ultra-Premium Handcrafted Vodka, an all-American spirit with federal approval to advertise its gluten-free status right on the label. It’s scheduled for release in August.

ASCC’s plans for its wholly owned distributor go much farther than that, however. It is anticipated that TOP Shelf Distributing will market additional outside distilled spirits brands as well as importing beer and wine for discerning consumers in select markets.

“The explosion in niche spirits and microbrews in recent years has opened up a huge market of connoisseurs interested in a variety of premium beverages,” said ASCC CEO Robert Federowicz. “We expect that handling our own distribution business will lead to unprecedented new brand building opportunities for Luxuria Brands and ASCC.”

For more information, visit www.aristocratgroupcorp.com

DoMark International Inc. (DOMK) Reports Strong Demand for New IRCharger Cover

DoMark International, a leader in infrared/solar charging systems for Apple (AAPL) and Samsung (KOSCOM:SSNFL) devices, today announced that it has received 158,000 orders for its new IRCharger case for Apple iPhones and Samsung Galaxy Slll and S4 smartphones prior to its upcoming global launch date.

“Our global distribution partners have been receiving great interest for the product from retailers and we are expecting to be able to announce many more orders shortly,” Domark CEO Andy Ritchie said.

The new IR Charger Case, which has a release date of August 1, 2013, features innovative patent pending INFRASOLTM technology utilizing infrared and solar charging features. The case is also backed up with two high density lithium batteries providing an additional doubling of battery life for both Apple iPhone and Samsung Galaxy devices. DoMark International’s new product will retail at a very competitive price of $59.99 USD. For more information, visit www.IRcharger.com.

When estimating market potential, keep in mind that Apple sold 125 million iPhone’s in 2012 and Samsung sold 40 million Galaxy smartphones in the first 6 months since launch globally. DoMark CEO, Andy Ritchie, stated, “There is nothing in the market like this product, and we are very encouraged by the orders received to date, and are expecting to announce many more in the future. DoMark has invested in five great innovative products, and we are well positioned to return substantial growth for our investors.”

For more information, visit www.domarkintl.com

VistaGen Therapeutics, Inc. (VSTA) Shares Exciting CardioSafe 3Dô and LiverSafe 3Dô Developments at ISSCRís 11th Annual Meeting

VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism assays, recently delivered an overview of key developments involving its CardioSafe 3D™ and LiverSafe 3D™ bioassay systems in poster presentations at the 11th Annual Meeting of the International Society of Stem Cell Research (ISSCR), the largest forum for stem cell and regenerative medicine professionals from around the world, held last week in Boston, Massachusetts.

Dr. Hai-Qing Xian, Senior Scientist, presented VistaGen’s poster entitled “Cardiotoxicity Assessment of Anti-Cancer Kinase Inhibitors using Human Pluripotent Stem Cell-Derived Cardiomyocyte Based Assays,” which detailed important developments demonstrating that CardioSafe 3D™, VistaGen’s high throughput, human heart cell-based bioassay, is a clinically predictive system for preclinical cardiac safety screening of anti-cancer drug candidates, including small molecule kinase inhibitors (KIs), a new category of drugs that have revolutionized cancer therapy due to decreased systemic toxicity and increased target cell efficacy compared to classic cancer drugs, as well as other therapeutic compounds. VistaGen also demonstrated the utility of CardioSafe 3D™ to detect cardiac toxicities of well-known anti-cancer KIs, including imatinib, dasatinib, sunitinib, erlotinib, and temsirolimus, which have been associated with adverse clinical cardiac events that were not detected during the drug development process. As demonstrated in the poster presentation, CardioSafe 3D™ successfully detected cardiotoxicity induced by representative compounds from different KI categories. Additionally, the bioassay system provided clues to the major mechanisms of cardiac cytotoxicity induced by each compound, thus enabling not only the identification of toxicities early in the drug development process, but also discovery of potential mechanisms of action.

Dr. Kristina Bonham, Senior Scientist, Hepatocyte Biology Project Leader, presented VistaGen’s poster entitled “Semi–quantitative assay of CYP3A4 allows the identification and selection of mature human stem cell derived hepatocytes,” which detailed developments indicating that LiverSafe 3D™, VistaGen’s human liver cell-based bioassay, can monitor the induction of the key metabolic enzyme, CYP3A4, and its expression level over time. Using an optimized protocol for the differentiation of hepatocyte-like cells, VistaGen demonstrated levels of CYP3A4 mRNA approaching that in human adult liver on a per cell basis. The reported data suggest that VistaGen’s liver cells have many of the functional properties of mature adult liver cells, enabling multiple functional analyses and providing a powerful system to evaluate the effects of drug candidates on CYP3A4 expression and liver function, offering a valuable aid for assessing potential drug candidates for toxicity and adverse drug-drug interactions.

H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer, emphasized, “For the first time, our technology has caught up with the dreams and visions we had 15 years ago when we founded VistaGen. We now have the type and quality of human cell-based biological assay systems that provide real insight into both the therapeutic and toxic effects of new drug candidates long before they are ever tested in humans. Next-generation biological assays can now provide important preclinical human data that will increase the probability of selecting safer and effective therapeutics for clinical development.”

“It is evident from the mood, tone and scientific discussions throughout the ISSCR conference that this is the most exciting time in the history of stem cell research,” added Dr. Snodgrass. “We anticipate that we will see an explosion over the next ten years in the contribution of human pluripotent stem cell-based biological assays to drug development, in parallel with phenomenal advancements in the therapeutic uses of mature cells and tissues derived from human pluripotent stem cells to treat some of the most intractable human diseases and conditions. Our team is truly fortunate and excited about being a part of this transformational process.”

For more information, visit www.vistagen.com

International Stem Cell Corp. (ISCO) Applies Broad Stem Cell IP Portfolio to Three Key Markets

Biotech small-cap International Stem Cell Corp. uses unfertilized eggs to develop therapies to treat diseases of the brain, liver, and the eye. By using unfertilized eggs to create human pluripotent stem cells, the company’s core technology avoids the controversial use of viable human embryos.

As noted above, the company is focused on three key markets:

The company is in pre-clinical stages for its treatment of Parkinson’s disease. Parkinson’s disease is the second most prevalent neurodegenerative diseases, effecting 4 percent of the population over the age of 50. The company says the origin of the disease and its relative localization in the brain makes this an attractive target for stem cell therapy.

Chronic liver disease, including hepatitis C, is the third most common cause of death due to chronic diseases in persons 35 to 64 years old. The company is in pre-clinical stage for its treatment of liver disease with stem-cell derived hepatocytes, a cell that makes up 70-85 percent of the liver’s cytoplasmic mass.

The company notes a large unmet medical need for the treatment of blindness with corneal tissue. Approximately 10 million people in the world are blind because of damage to their cornea. ISCO is in pre-clinical stage to produce cornea tissue implants. The company has developed and filed patents on a process that creates human corneal tissue from parthenogenetic stem cells, closely resembling a human cornea in structure and cell types.

As of April 13, 2012, the company had 90 pending patent applications across eight patent families, and three pending patents related to its skin care products. ISCO also has licensed a portfolio of 128 international patents or patent applications across 30 patent families.

For more information, visit www.internationalstemcell.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Club Penny Stocks Network





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251